Self-aligning peptides modeled on human elastin and other fibrous proteins |
| OF PREFERRED EMBODIMENTS The present invention is directed to unique polypeptides modeled on human ... |
|
Prosthetic devices including elastin or elastin-based materials |
| It is a specific object of the invention to provide an elastin-based prosthetic device suitable for ... |
|
Peptides containing N-substituted L-amino acids for preventing .beta.-strand association |
| The invention claimed is: 1. A peptide comprising a peptide, wherein: (a) said peptide comprises a .... |
|
Lectins and antiretroviral drugs containing the lectins as active ingredient |
| OF THE INVENTION The lectins of the present invention are obtained from the plants of the class D... |
|
Activated dendritic cells and methods for their activation |
| The present invention pertains to a method of activating dendritic cells to enhance antigen ... |
|
Methods and compositions for obtaining mature dendritic cells |
| OF THE INVENTION This invention relates to methods and compositions useful for promoting the ... |
|
Nucleic acid encoding a lectin-derived progenitor cell preservation factor |
| It has now been discovered that these and other objectives can be achieved by the present invention,... |
|
Ligand for vascular endothelial growth factor receptor |
| We claim: 1. A compound comprising amino acid sequence Glu-Ile-Glu-Trp-Tyr-Ser-Trp-Val-Thr-His-Gly-M... |
|
Immunoliposomes that optimize internalization into target cells |
| The present invention provides novel immunoliposomes optimized for delivering therapeutic agents to ... |
|
|
Stimulation of chemotaxis by chemotactic peptides
| Details |
Inventors: Urry, Dan W.; Long, Marianna;
Assignee: UAB Research Foundation (Birmingham, AL)
Primary Examiner: Cannon; Alan W.
Assistant Examiner:
Attorney, Agent or Firm: Neeley; Richard L.
A method of stimulating chemotaxis toward a prosthetic device is disclosed, which method comprises incorporating a chemotactic peptide of the formula B.sup.1 -X-(AGVPGLGVG).sub.n -(AGVPGFGVG).sub.m -Y-B.sup.2 wherein A is a peptide-forming residue of L-alanine; P is a peptide-forming residue of L-proline; G is a peptide-forming residue of glycine; V is a peptide-forming residue of L-valine; F is a peptide-forming residue of L-phenylalanine; L is a peptide-forming residue of L-leucine; B.sup.1 is H or a biocompatible N-terminal group; B.sup.2 is OH, OB.sup.3 where B.sup.3 is a non-toxic metal ion, or a biocompatible C-terminal group; X is GVPGFGVG, GVPGLGVG, VPGFGVG, VPGLGVG, PGFGVG, PGLGVG, GFGVG, GLGVG, FGVG, LGVG, GVG, VG, G or a covalent bond; Y is AGVPGFGV, AGVPGLGV, AGVPGFG, AGVPGLG, AGVPGF, AGVPGL, AGVPG, AGVP, AGV, AG, A or a covalent bond; n is an integer from 0 to 50; m is an integer from 0 to 50; with the proviso that when both n and m are O, X and Y are selected so that the chemotactic peptide has at least 3 amino acid residues in the X and Y positions combined; into a surface of a prosthetic device. Prosthetic devices which have the property of enhancing invasion of fibroblasts and endothelial cells as a result of the chemotactic peptide are also disclosed. |
|
DETAILED DESCRIPTION Accordingly, it is an object of this invention to provide a synthetic material having chemotactic properties towards cells such as fibroblasts and endothelial cells. It is a further object of this invention to provide a prosthetic device which is readily incorporated into regenerating tissue, such as skin or blood vessel walls. It is still another object of this invention to provide a chemotactic material having stimulating activity to a greater extent than was previously available. These and other objects of the invention as will hereinafter become more readily apparent have been accomplished by providing a method of stimulating chemotaxis, which comprises: incorporating a chemotactic peptide of the formula B. sup. 1 -X-(AGVPGLGVG). sub. n -(AGVPGFGVG). sub. m -Y-B. sup. 2 wherein A is a peptide-forming residue of L-alanine; P is a peptide-forming residue of L-proline; G is a peptide-forming residue of glycine; V is a peptide-forming residue of L-valine; F is a peptide-forming residue of L-phenylalanine; L is a peptide-forming residue of L-leucine; B. sup. 1 is H or a biocompatible N-terminal group; B. sup. 2 is OH, OB. sup. 3 where B. sup. 3 is a non-toxic metal ion, or a biocompatible C-terminal group: X is GVPGFGVG, GVPGLGVG, VPGFGVG, VPGLGVG, PGFGVG, PGLGVG, GFGVG, GLGVG, FGVG, LGVG, GVG, VG, G or a covalent bond; Y is AGVPGFGV, AGVPGLGV, AGVPGFG, AGVPGLG, AGVPGF, AGVPGL, AGVPG, AGVP, AGV, AG, A or a covalent bond; n is an integer from 0 to 50; m is an integer from 0 to 50; with the proviso that when both n and m are 0, X and Y are selected so that the chemotactic peptide has at least 3 amino acid residues in the X and Y positions combined; into a layer of a prosthetic device in an amount sufficient to increase chemotaxis towards said layer. This invention also comprises chemotactic matrices and prosthetic devices prepared according to the method set forth above.
|
| Related patents |
|
|
Biological material pre-fixation treatment
OF PREFERRED EMBODIMENTS In one aspect, the present invention relates to an improved bioprosthetic heart valve having an improved resistance to post-implantation ...
|
|
|
Diagnosis of Williams syndrome
OF THE INVENTION The present invention is directed to the determination that SVAS and Williams syndrome map to the elastin gene and that molecular variants of the ...
|
|
|
Biological material pre-fixation treatment
OF PREFERRED EMBODIMENTS In one aspect, the present invention relates to an improved bioprosthetic heart valve having an improved resistance to post-implantation ...
|
|
|
Method for bonding or fusion of biological tissue and material
Biological materials are joined, repaired or fused by heating the material in proximity to a mechanical support. In the preferred embodiment, the mechanical support ...
|
|
|
Diagnosis and treatment of supravalvular aortic stenosis and Williams syndrome
OF THE INVENTION The present invention is directed to the determination that SVAS and Williams syndrome map to the elastin gene and that molecular variants of the ...
|
|
|
Biological material pre-fixation treatment
OF PREFERRED EMBODIMENTS In one aspect, the present invention relates to an improved bioprosthetic heart valve having an improved resistance to post-implantation ...
|
|
|
Matrix substrate for a viable body tissue-derived prosthesis and method for making the same
OF THE INVENTION The present invention covers a process that thoroughly removes intact cells from body tissues such as vascular structures including the porcine heart ...
|
|
|
Barrier webs having bioactive surfaces
What is claimed is: 1. A bioactive substrate comprising: a support; and a bioactive surface thereon, wherein the bioactive surface comprises: a shear-thinable, ...
|
|
|
Biopolymer foams for use in tissue repair and reconstruction
OF THE INVENTION The present invention features biopolymer foams, composite biopolymer foams, biocompatible constructs comprising biopolymer foams and extracellular ...
|
|
|
Periodate oxidative method for attachment of biomolecules to medical device surfaces
OF THE INVENTION As used in the specification and claims hereof, the following terms have the particular meanings and definitions set forth below. I define the term "...
|
|
|